INTRODUCTION: Salmonella enterica serovar Typhi is the causative agent of typhoid fever with over 22 million cases and over 200,000 deaths reported annually. A vaccine is much needed for use in young children and the Novartis Vaccines Institute for Global Health (NVGH) is developing a conjugate vaccine which targets S. Typhi Vi capsular polysaccharide. METHODOLOGY: Here we describe a method suitable for industrial scale production of the Vi antigen based on expression by a Citrobacter line. We optimized the production of Vi by selecting a suitable Citrobacter strain (Citrobacter 328) that yields high and stable expression of Vi in chemically defined medium under industrial-scale fermentation conditions. RESULTS: Vi-CRM197 made using Vi from Citrobacter 328 elicited high anti-Vi antibody levels in mice and rabbits. CONCLUSIONS: Citrobacter 328 is a suitable strain for production of Vi for conjugate anti-Typhi vaccines. Being a BSL-1 organism, which grows in defined medium and stably produces high yields of Vi, it offers excellent potential for safe production of inexpensive vaccines for populations at risk of typhoid fever.
INTRODUCTION:Salmonella enterica serovar Typhi is the causative agent of typhoid fever with over 22 million cases and over 200,000 deaths reported annually. A vaccine is much needed for use in young children and the Novartis Vaccines Institute for Global Health (NVGH) is developing a conjugate vaccine which targets S. Typhi Vi capsular polysaccharide. METHODOLOGY: Here we describe a method suitable for industrial scale production of the Vi antigen based on expression by a Citrobacter line. We optimized the production of Vi by selecting a suitable Citrobacter strain (Citrobacter 328) that yields high and stable expression of Vi in chemically defined medium under industrial-scale fermentation conditions. RESULTS: Vi-CRM197 made using Vi from Citrobacter 328 elicited high anti-Vi antibody levels in mice and rabbits. CONCLUSIONS:Citrobacter 328 is a suitable strain for production of Vi for conjugate anti-Typhi vaccines. Being a BSL-1 organism, which grows in defined medium and stably produces high yields of Vi, it offers excellent potential for safe production of inexpensive vaccines for populations at risk of typhoid fever.
Authors: Thomas J Griffin; Ann Thanawastien; Robert T Cartee; John J Mekalanos; Kevin P Killeen Journal: Hum Vaccin Immunother Date: 2019-05-28 Impact factor: 3.452
Authors: Abhilasha Karkey; Corinne N Thompson; Nga Tran Vu Thieu; Sabina Dongol; Tu Le Thi Phuong; Phat Voong Vinh; Amit Arjyal; Laura B Martin; Simona Rondini; Jeremy J Farrar; Christiane Dolecek; Buddha Basnyat; Stephen Baker Journal: PLoS Negl Trop Dis Date: 2013-08-22
Authors: Nga Tran Vu Thieu; Tan Trinh Van; Anh Tran Tuan; Elizabeth J Klemm; Chau Nguyen Ngoc Minh; Phat Voong Vinh; Duy Pham Thanh; Thanh Ho Ngoc Dan; Trung Pham Duc; Pinky Langat; Laura B Martin; Jorge Galan; Li Liang; Philip L Felgner; D Huw Davies; Hanna K de Jong; Rapeephan R Maude; Masako Fukushima; Lalith Wijedoru; Aniruddha Ghose; Rasheda Samad; Arjen M Dondorp; Abul Faiz; Thomas C Darton; Andrew J Pollard; Guy E Thwaites; Gordon Dougan; Christopher M Parry; Stephen Baker Journal: J Infect Date: 2017-05-25 Impact factor: 6.072
Authors: Francesca Micoli; Stefania P Bjarnarson; Melissa Arcuri; Audur Anna Aradottir Pind; Gudbjorg J Magnusdottir; Francesca Necchi; Roberta Di Benedetto; Martina Carducci; Fabiola Schiavo; Carlo Giannelli; Ivan Pisoni; Laura B Martin; Giuseppe Del Giudice; Calman A MacLennan; Rino Rappuoli; Ingileif Jonsdottir; Allan Saul Journal: Proc Natl Acad Sci U S A Date: 2020-09-08 Impact factor: 11.205